Answers are grounded in this paper and cite their sources.
In patients with RM-NPC, apatinib plus camrelizumab showed promising antitumor activity and manageable toxicities.
No takes yet. Share an insight, caveat, or question.
Mo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: